Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.

@article{Schaik2014InfluenceOC,
  title={Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.},
  author={Tamara van Schaik and Jeroen P W J Maljaars and Rajiv K Roopram and Marthe H Verwey and Nienke Ipenburg and James Ch Hardwick and Roeland A. Veenendaal and Andrea E. van der Meulen-de Jong},
  journal={Inflammatory bowel diseases},
  year={2014},
  volume={20 12},
  pages={
          2292-8
        }
}
BACKGROUND It is important to identify factors that can reduce the incidence of immunogenicity against anti-tumor necrosis factor medication in patients with inflammatory bowel disease. The objective of our study was to evaluate the influence of cotreatment with immune modulators (IMs) on trough levels (TLs) and antidrug antibodies. METHODS The records of all patients with inflammatory bowel disease at the Leiden University Medical Center who received either adalimumab or infliximab (IFX) in… CONTINUE READING